These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 9058819)

  • 21. IL-10 inhibits tumor antigen presentation by epidermal antigen-presenting cells.
    Beissert S; Hosoi J; Grabbe S; Asahina A; Granstein RD
    J Immunol; 1995 Feb; 154(3):1280-6. PubMed ID: 7822797
    [TBL] [Abstract][Full Text] [Related]  

  • 22. B7-1 expression decreases tumorigenicity and induces partial systemic immunity to murine neuroblastoma deficient in major histocompatibility complex and costimulatory molecules.
    Katsanis E; Xu Z; Bausero MA; Dancisak BB; Gorden KB; Davis G; Gray GS; Orchard PJ; Blazar BR
    Cancer Gene Ther; 1995 Mar; 2(1):39-46. PubMed ID: 7542553
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Superiority of interleukin-12-transduced murine lung cancer cells to GM-CSF or B7-1 (CD80) transfectants for therapeutic antitumor immunity in syngeneic immunocompetent mice.
    Sumimoto H; Tani K; Nakazaki Y; Tanabe T; Hibino H; Wu MS; Izawa K; Hamada H; Asano S
    Cancer Gene Ther; 1998; 5(1):29-37. PubMed ID: 9476964
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Live cell vaccines expressing B7.1, monocyte chemoattractant protein 1 and granulocyte-macrophage colony stimulation factor derived from mouse HPV16-transformed cells.
    Lakatosová-Andelová M; Jinoch P; Dusková M; Marinov I; Vonka V
    Int J Oncol; 2008 Jan; 32(1):265-71. PubMed ID: 18097567
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protective immunity induced by B7/CD28-costimulated gamma delta T cells to the EL-4 lymphoma in allogenic athymic mice.
    Li Y; Newby SA; Johnston JV; Hellström KE; Chen L
    J Immunol; 1995 Dec; 155(12):5705-10. PubMed ID: 7499857
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity.
    Aarts WM; Schlom J; Hodge JW
    Cancer Res; 2002 Oct; 62(20):5770-7. PubMed ID: 12384537
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Major histocompatibility complex class I presentation of exogenously acquired minor alloantigens initiates skin allograft rejection.
    Oukka M; Galou M; Belkaid Y; Tricotet V; Riche N; Reynes M; Kosmatopoulos K
    Eur J Immunol; 1997 Dec; 27(12):3499-506. PubMed ID: 9464840
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The expression of CD70 and CD80 by gene-modified tumor cells induces an antitumor response depending on the MHC status.
    Douin-Echinard V; Bornes S; Rochaix P; Tilkin AF; Peron JM; Bonnet J; Favre G; Couderc B
    Cancer Gene Ther; 2000 Dec; 7(12):1543-56. PubMed ID: 11228533
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Route of administration influences the antitumor effects of bone marrow-derived dendritic cells engineered to produce interleukin-12 in a metastatic mouse prostate cancer model.
    Saika T; Satoh T; Kusaka N; Ebara S; Mouraviev VB; Timme TL; Thompson TC
    Cancer Gene Ther; 2004 May; 11(5):317-24. PubMed ID: 15044961
    [TBL] [Abstract][Full Text] [Related]  

  • 30. H-2K double transfectants of tumor cells as antimetastatic cellular vaccines in heterozygous recipients. Implications for the T cell repertoire.
    Mandelboim O; Feldman M; Eisenbach L
    J Immunol; 1992 Jun; 148(11):3666-73. PubMed ID: 1588053
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A double recombinant adenovirus expressing the costimulatory molecule B7-1 (murine) and human IL-2 induces complete tumor regression in a murine breast adenocarcinoma model.
    Emtage PC; Wan Y; Bramson JL; Graham FL; Gauldie J
    J Immunol; 1998 Mar; 160(5):2531-8. PubMed ID: 9498799
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Kinetics of cytokine gene expression during the in vitro CTL induction against a murine nonimmunogenic tumor.
    Murata S; Eguchi Y; Mekata E; Tani T; Kodama M
    Anticancer Res; 2000; 20(1A):363-72. PubMed ID: 10769681
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
    Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
    Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Deoxyribonucleic acid vaccines encoding antigens with rapid proteasome-dependent degradation are highly efficient inducers of cytolytic T lymphocytes.
    Wu Y; Kipps TJ
    J Immunol; 1997 Dec; 159(12):6037-43. PubMed ID: 9550402
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, and gamma-interferon gene or admixed with conventional adjuvants.
    Allione A; Consalvo M; Nanni P; Lollini PL; Cavallo F; Giovarelli M; Forni M; Gulino A; Colombo MP; Dellabona P
    Cancer Res; 1994 Dec; 54(23):6022-6. PubMed ID: 7954438
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
    Wang J; Saffold S; Cao X; Krauss J; Chen W
    J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Studies using antigen-presenting cells lacking expression of both B7-1 (CD80) and B7-2 (CD86) show distinct requirements for B7 molecules during priming versus restimulation of Th2 but not Th1 cytokine production.
    Schweitzer AN; Sharpe AH
    J Immunol; 1998 Sep; 161(6):2762-71. PubMed ID: 9743334
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rejection of a nonimmunogenic melanoma by vaccination with natural melanoma peptides on engineered antigen-presenting cells.
    Bellone M; Iezzi G; Martin-Fontecha A; Rivolta L; Manfredi AA; Protti MP; Freschi M; Dellabona P; Casorati G; Rugarli C
    J Immunol; 1997 Jan; 158(2):783-9. PubMed ID: 8992995
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokine genes.
    Chow YH; Chiang BL; Lee YL; Chi WK; Lin WC; Chen YT; Tao MH
    J Immunol; 1998 Feb; 160(3):1320-9. PubMed ID: 9570550
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modulation of host immune responses stimulated by Salmonella vaccine carrier strains by using different promoters to drive the expression of the recombinant antigen.
    Medina E; Paglia P; Rohde M; Colombo MP; Guzmán CA
    Eur J Immunol; 2000 Mar; 30(3):768-77. PubMed ID: 10741391
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.